**About the Editors**

**Paul Quax** (PhD) obtained his PhD at the University of Leiden, the Netherlands, on the role of plasminogen activators in tissue remodeling. He kept on working on this topic in relation to vascular remodeling, first at the Gaubius Laboratory TNO and later at the Leiden University Medical Center as professor in experimental vascular medicine. His interest in arteriogenesis was driven by the lack of therapeutic options for patients with peripheral arterial disease. Therapeutic arteriogenesis and angiogenesis induced by gene therapy, growth factors, modulation of inflammatory and immune response but also by modulation of microRNAs and other noncoding RNAs in small animal model are topics of his research.

**Elisabeth Deindl** (Dr) graduated at the ZMBH in Heidelberg, Germany, where she worked on hepatitis B viruses. Thereafter, she joined the lab of Wolfgang Schaper at the Max-Planck-Institute in Bad Nauheim, where she started to decipher the molecular mechanisms of arteriogenesis. After a short detour on stem cells, she focused again on arteriogenesis becoming a leading expert in the field. By using a peripheral model of arteriogenesis, she demonstrated that collateral artery growth is a matter of innate immunity and presents a blueprint of sterile inflammation, which is locally triggered by extracellular RNA.
